Novel LNP Formulation Targets Spleen, Boosts Immune Response
Vaccine-optimised Nucleic Acid Delivery Technology
Tags: Monash University, Australia, Science & Exploration, Healthcare & Lifesciences
This lipid nanoparticle (LNP) formulation enhances delivery of nucleic acids, like mRNA, to the spleen, boosting immune responses for vaccines and cancer immunotherapies. Unlike conventional LNPs that target the liver, this novel formulation is designed for spleen targeting, where it can more effectively activate T and B cells. The proprietary mix includes a unique lipopeptide, simplifying manufacture while directing the therapeutic payload to the spleen. Applications include mRNA vaccinations against infectious diseases and various cancer treatments. Completed Phase 1 trials show its potential for improving vaccine efficacy and cancer therapy outcomes.
IP Type or Form Factor: Patent Pending; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Nanotechnology; Vaccines
